

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) **PCT**

			THE DATENT COOPERALL	014 1142-11
INTERNATIONAL APPLICATION P	UBLISHED	JNDER 	THE PATENT COOPER	WO 92/03971
(51) International Patent Classification 5:	} '	(11) Inte	manunar a come	19 March 1992 (19.03.92)
A61B 8/06, 5/00, G10K 11/24		L		ean patent), BE (European
(21) International Application Number	CT/US91/062 st 1991 (29.08.		Designated States: AT (Europe patent), CH (European patent), ES (European patent), ES (ropean patent), GB (European patent), GB (Eur	(m' natent) PK (Cu-
And Valenctional Filing Date: 29 Augu	•• • •	1	tohean baronthi	nt) IP LU (European Pa-

(22) International Filing Date:

7 September 1990 (07.09.90) (30) Priority data: US 579,428

(71) Applicant: HEWLETT-PACKARD COMPANY [US/US]; 3000 Hanover Street, Palo Alto, CA 94304 (US).

(72) Inventor: DIAZ, J., Fleming; 251 Iris Way, Palo Alto, CA 94303 (US).

(74) Agents: WU, Jack, H. et al.; Hewlett-Packard Company, Legal Department, M/S 20BO, 3000 Hanover Street, Palo Alto, CA 94304 (US).


DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report. Mun international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: ACOUSTIC FIBER MEASUREMENT OF INTRAVASCULAR BLOOD



(57) Abstract

One or more acoustic fiber guides (725-1) are used to carry certain modes of acoustic energy to the tip of a disposable catheter. Using these fibers, reflected sound (Doppler Sound) measurements are made in a blood environment (701) without the risk to the patient associated with the use of an electrical transducer at the distal end of the catheter. Due to the size reduction provided, the Doppler probe is suitable for monitoring the blood flow in the coronary arteries. By the addition of optical fibers (725-2) tipped with specific dyes and excited by optical energy of appropriate wavelength, the catheter tip system can also be utilized simultaneously as a combined (integral) optical blood gas and pH monitor using optical fluorescence and an acoustic Doppler velocity transducer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	PI	Finland	ML.	Mali .
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	CB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic	SE	Sweden
CH	Switzerland		of Korea	SN	Senegal
CI	Côte d'ivoire	KR	Republic of Korca	su+	Soviet Union
CM	Cameroon	Ll	Liechtenstein	TD	Chad
cs	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE*	Germany	LU	Luxembourg	US	United States of America
n.v	Denomark	MC	Mannen		

⁺ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

WO 92/03971 PCT/US91/06206

1

5

ACOUSTIC FIBER MEASUREMENT OF INTRAVASCULAR BLOOD

10

15

30

35

INTRODUCTION

Technical Field

This invention pertains to catheter devices and more specifically to catheter devices useful for a combined in vivo measurement of blood gas velocity and blood composition.

Background of the Invention

20 It is known in the prior art how to measure blood velocity utilizing a catheter having a piezoelectric transducer (such as PZT) at its tip. The piezoelectric material is generally lead zirconate titanate which is a type of ceramic. A typical transducer 100 has two active faces 101 and 102, as shown in Figure 1.

These faces are metallized by vacuum depositing thin films of chromium (200 Å) and gold (2000 Å). Leads 103, 104 are then attached to faces 101, 102, respectively. When connected to a pulse generator 107, transducer 100 converts the electrical signals into acoustic pulses 105, 106. If acoustic pulse 105 is designated as being in the forward direction, the acoustic pulse 106 is either damped (for example, by placing a suitable damping material on face 102 of transducer 100, as is well known in the art), or pulse 106 is forced to be reflected in a forward direction in order to add to the energy provided by forward pulse 105. Pulse 106 is

WO 92/03971 2 PCT/US91/06206

reflected, for example, by adding impedance mismatch, for example, by placing transducer 100 such that face 102 is exposed to the ambient environment. The reverse is also true - i.e. an acoustic pulse impinging on either face 101 or 102 creates an electrical signal on leads 103, 104. Such PZT transducers are generally circular or annular when used at the tip of a catheter. Thickness 108 of transducer 100 determines the operating frequency - at 20 MHz the thickness is about 0.1 mm.

catheter device, including PZT transducer 203 located at its distal end which, as shown in Figure 2, has been inserted into blood vessel 204. Electrical connection 202 is contained within catheter 200 and serves to connect PZT transducer 203 to external circuitry (not shown) after exiting from proximal end 201 of catheter 200. As sound energy is emitted from PZT transducer 203, sound is reflected by the red blood cells contained within blood vessel 204, thereby causing a received electrical signal to be generated on electrical lead 202, which can then be detected by external circuitry. This detected signal is indicative of blood velocity.

The fabrication of these prior art PZT transducers is difficult and entails a significant amount of labor. While the use of higher frequencies results in a better signal to noise ratio, using such prior art transducers at higher frequencies presents a size problem, because the thickness scales downwards. At higher frequencies, such prior art PZT transducers are, for all practical purposes, impossible to manufacture economically. For example, at 40 MHz, the transducer thickness would be about 2 mils (0.05 mm). Moreover, there is always a risk to the patient at all frequencies because of the existence of an electrical potential at the distal end of the catheter, which

WO 92/03971 3 PCT/US91/06206

introduces the risk of fibrillation, particularly when measuring blood flow near the coronary arteries. such prior art devices, the PZT transducer at the tip of the catheter is connected to appropriate instrumentation by electrical wires, which inherently 5 act as antennas which receive radio frequency interference which is likely to be present in a catheterization laboratory. This RF interference is undesirably coupled to the PZT by introducing noise in the circuitry and also further increasing the risk 10 of fibrillation. Furthermore, for sterility, the catheter must be disposable; with such a prior art device, disposing of the catheter necessitates disposing of the transducer, resulting in excessive cost. 15

In intravascular measurements, this system can measure the blood velocity, the flow rate at the proximal end of the coronary arteries, and in some cases it will provide an indication of an occluded blood vessel. The more successful attempts at imaging, use a PZT transducer with a rotating mirror, as described in "Laser Angioplasty's Ingeneous Hardware," CARDIO (August 1988); "Improved Monitoring of Laser Angioplasty with Laser Doppler Echocardiography," Bommer et al., Journal of the American College of Cardiology, (Feb. 1988) 11:No. 2;

and "Intra-arterial Ultrasonic Imaging for

Recanalization by Spark Erosion," Ultrasound in

20

25

30

35

Medicine and Biology (1988) 14:257-261.

To reach the quasi-distal end of the coronary arteries, the outer diameter of the catheter must not be larger than about 1.5 mm. Clearly there is an urgent need to greatly diminish the size of the Doppler catheter, especially if the ultimate objective is to explore the coronary vasculature. This objective becomes more important when the measurement of velocity or change of velocity is to be observed when a vasodilator is administered at the distal end

WO 92/03971 4 PCT/US91/06206

of the catheter. Consequently, the PZT transducers used in the prior art had to be extremely small.

It has been shown by C. K. Jen, in "Similarities and Differences between Acoustics and Fiber Optics", IEEE Ultrasonics Symposium 1985, that conventional multimode "optical fibers" can also propagate acoustic longitudinal and shear pulses, and provide round trip acoustical transmission.

5

10

15

20

25

30

35

It is also well documented in the literature that similar optical fibers when excited by laser energy can utilize optical fluorescence techniques to monitor the concentration of blood gases like oxygen and carbon dioxide. These techniques are described in "Optical Fluorescence and its Application to an Intravascular Blood Gas Monitoring System" by John L. Gehrich, et al., in IEEE Transactions on Biomedical Engineering, Vol. BME-33, No. 2, Feb. 1986.

It would be of significant advantage to the medical profession to have a combined probe that measures the blood flow velocity and monitors the O2 and CO2 concentration in the blood without using any active electrical components at the tip of the intravascular catheter. Such a probe would provide an invaluable and reliable tool for the patient care of the critically ill, by enabling the intravascular surgeon to make quick and accurate diagnosis.

The basic principle involved in a monitoring sensor is the fluorescence of a dye which is specific to the gas being monitored. The wavelength of the emitted fluorescence is always lower than that of the input laser excitation and consequently a single optical fiber can be used to transmit the light through the fiber and receive the light emitted by the fluorescent dye. The intensity of the emitted light is inversely proportional to the gas concentration. In practical applications, the distal tip of the fiber is coated with the specific dye and it is protected by an external coating. Different dyes are available for

WO 92/03971 5 PCT/US91/06206

monitoring the pH, O_2 and CO_2 concentrations in the blood.

SUMMARY OF THE INVENTION

5

. 10

15

20

25

30

In accordance with the teachings of this invention, a novel solution to the problems stated above is achieved by providing acoustic excitation at the catheter tip without the use of any electrically active devices. One or more acoustic fiber guides are used to carry certain modes of acoustic energy to the tip of the catheter. Using these fibers, reflected sound (Doppler sound) measurements are made in a blood environment without the risk to the patient associated with the use of an electrical transducer at the distal end of the catheter. Moreover, the fiber within the catheter does not pick up any radio frequency interference that might be present in a catheterization laboratory, because the signal transfer takes place via an acoustical fiber.

In accordance with the teachings of this invention, a Doppler probe is provided which is fitted at the end of a catheter that is less than approximately 1.00 mm OD, in which acoustical energy is generated outside of the patient and transported to the distal end of the catheter by an acoustic fiber. Due to this size reduction provided in accordance with the teachings of this invention, the Doppler probe of this invention is suitable for monitoring the blood flow in the coronary arteries. Using this invention wherein sound is transported to the catheter tip by an acoustic fiber, risk is reduced and the catheter is significantly less expensive, and therefore can be treated as disposable.

By the addition of optical fibers tipped

with specific dyes and excited by optical energy of appropriate wavelength, the catheter tip system of this invention can also be utilized simultaneously as a combined (integral) optical blood gas and pH

WO 92/03971 6 PCT/US91/06206

monitor using optical fluorescence and an acoustic Doppler velocity transducer.

The catheter tip system of this invention is suitable for use for Doppler signal analysis of the power spectrum, to determine the mean blood flow velocity and consequently the blood flow rate and cardiac output.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts a typical prior art PZT transducer;

5

10

15

20

25

30

35

Figure 2 depicts typical prior art catheter which has been used to insert a PZT sensor into the bloodstream of a patient;

Figure 3 depicts the use of a catheter for inserting within the bloodstream of a patient an acoustical sensor constructed in accordance with the teachings of this invention;

Figure 4 shows a cross-sectional and end views of one embodiment of an acoustical sensor constructed in accordance with the teachings of this invention;

Figure 5 is a graph depicting the relationship between doppler frequency and blood flow velocity, for two alternative excitation frequencies;

Figure 6 is a graph depicting the relationship between blood velocity and the distance of the range cell from the catheter tip for three alternative excitation frequencies; and

Figure 7 depicts an alternative embodiment of a catheter constructed in accordance with the teachings of this invention including a guide wire, an acoustical sensor, and optical fibers used to measure blood gas concentrations by optical fluorescence.

25

30

35

DETAILED DESCRIPTION

Doppler Flow Velocity Catheter Tip Transducer

Figure 3 depicts one embodiment of a 5 catheter device constructed in accordance with the teachings of this invention. Catheter 300 is inserted into a patient such that its distal end 303 is located within blood vessel 304. Catheter 300 comprises a typical prior art catheter, for example, 10 having a size number 3 French. Within catheter 300 is located an acoustical fiber 302, which in one embodiment comprises readily available optical fiber made of glass, for example. Optical fiber 302 exits catheter 300 at its proximal end 301, and is connected 15 to means 320 for generating and coupling acoustical energy into fiber 302 and for detecting reflected acoustical energy from the red blood cells.

Means 320 comprises, for example, a surface acoustic wave device with curvilinear electrodes as described in copending U.S. Patent Application Serial No. 07/352,517, filed May 16, 1989, on an invention of J. Fleming Dias entitled "Ultrasonic Catheter Guidance System", and assigned to Hewlett Packard Company.

This device, when excited electrically, generates acoustic pulses that travel on the surface of a PZT substrate. These pulses converge at the center of the curvilinear electrodes where the fiber is affixed. The acoustic energy from the pulses is coupled into the proximal end of the fiber and propagates to the distal end. The reflected acoustic pulses also propagate through the fiber onto the surface of the PZT substrate and are converted into returning electrical pulses by the same curvilinear electrodes.

As is apparent from the embodiment of Figure 3, a catheter device constructed in accordance with the teachings of this invention allows acoustical energy to be applied to the blood in blood vessel 304 and

WO 92/03971 8 PCT/US91/06206

reflected acoustical energy to be sampled within blood vessel 304 without the need for electrical energy to be provided within blood vessel 304 or, indeed, within the patient at all. All of the electrical manipulation is done in circuitry 320, with all of the energy within the patient and blood vessel 304 being acoustical, rather than electrical, energy.

5

40

One embodiment of an acoustic fiber transducer constructed in accordance with the teachings of this invention is shown in the side and 10 cross-sectional views of Figure 4. Acoustical transducer 400 includes optical fiber guide "T", which is used as a transmitter of excitation ultrasound energy fr to insonify a volume of blood 401. A multiplicity of receiving fibers R; are used 15 to receive the acoustic signal backscattered by the red blood corpuscles in the blood, which is shifted in frequency with respect to the excitation frequency. Receiving fibers R_{i} are shown fused at point 402 using standard optical techniques to form a twisted acoustic 20 coupler, such that a single optical fiber 403 is used to transmit the backscattered signal to detection equipment (as described above). This coupler adds all the received signals. The summed signal is Doppler shifted in frequency with respect to the excitation 25 energy, and the net frequency shift is given by equation (1), and for clarity the constant delay through the fiber is not indicated.

30
$$f_D = 2f_T \frac{V\cos\theta}{C}$$
; where (1)

fD = doppler shift in frequency of the backscattered acoustic energy;

 $f_{T} = frequency of the excitation energy;$

C = velocity of sound in blood

15

20

30

35

40

(1560 m/s);

 θ = angle between the excitation energy beam and the velocity vector of the blood; and

v = velocity of blood flow.

In the case of intravascular Doppler measurements, the catheter is almost collinear with the blood flow and therefore θ is approximately 0, and thus

 $f_{\rm D} \simeq \frac{2f_{\rm T}V}{C} \tag{2}$

The catheter tip Doppler device of this invention is useful in two modes of operation: A continuous wave mode, and a pulsed wave mode.

In a continuous wave mode, an estimate of blood velocity is obtained. In this mode, the backscattered sound comes from the full extent of the transmitted ultrasonic beam and therefore, while no range resolution is possible, there is no limit on the maximum velocity that can be measured. Figure 5 depicts a graph showing velocity of blood flow versus Doppler shift frequency corresponding to excitation ultrasonic beams having frequency fr equal to 30 MHz and 40 MHz, respectively. Because of the ability to use much higher frequency sound in accordance with the teachings of this invention, it is now possible to measure very low blood flow velocities. For example, as shown in Figure 5, using a 40 MHz acoustical excitation signal, blood flow velocity of approximately 0.25 m/s results in a 16 kHz Doppler shifted backscatter signal.

WO 92/03971 1 0 PCT/US91/06206

The frequency of 40 MHz was selected for several reasons:

- (1) to obtain a higher signal to noise
- (2) to measure a low blood flow velocity corresponding to a higher fp;
- (3) to prevent excessive attenuation of the acoustic signal through the blood; and
- (4) to a certain extent, to achieve directivity in aiming.

ratio;

5.

10

15

20

25

30

35

Naturally, the teachings of this invention are equally applicable for use with excitation signals having a wide range of frequencies, since the fiber will propagate these frequencies with comparable efficiency.

In the pulsed wave mode, the measurement of the blood flow velocity is localized to a small volume in the blood. A sequence of pulses, consisting of a few cycles at frequency f_T and at a suitable pulse repetition frequency, are transmitted by the distal end of the fiber into the blood. These acoustic pulses, as they propagate, reflect some energy back into the fibers. The frequency of the backscattered energy is Doppler shifted in frequency in direct proportion to the blood velocity V as shown in equation 1.

The location of the backscattered signal is determined by a variable delay range gate which defines the distance R of a range cell from the distal end face of the fiber. The length of the range cell is equal to the number of cycles in each pulse and the area is nominally proportional to the sectional area of the fiber. Consequently the volume of the range cells is the product of the two.

In the pulsed mode of operation there is a limit on the maximum velocity $\boldsymbol{V}_{\boldsymbol{m}}$ that can be measured

10

15

20

before aliasing takes place. Aliasing is simply an ambiguity in determining the velocity and it is set by the sampling theorem which dictates that the pulse repetition frequency should be at least twice the Doppler shift in frequency.

The length of the range cell from which the backscattered sound is received is determined by the pulse length. Hence, unlike an imaging situation where a short pulse length is necessary to obtain optimum in-line resolution, a longer pulse is required to increase the received signal. Figure 6 shows a plot of velocity Vm as a function of the distance R of the range cell from the catheter tip, related to pulse repetition frequency.

The maximum velocity $V_{\rm m}$ of the blood that can be measured without frequency aliasing is given by

$$v_{m} = \frac{c^{2}}{8f_{m}R} \qquad ; \text{ where} \qquad (3)$$

C = the speed of acoustical signals in blood (typically 1560 m/s)

25 Thus, in a 40 MHz acoustic fiber pulsed system, where the range cell is located 0.5 cm away from the tip (by adjusting the pulse repetition frequency),

$$v_m = 1.5 \text{ m/s}.$$

30

This value of V_m falls in the ranges given in "Doppler Ultrasound in Cardiology," <u>Physical Principles and Clinical Application</u>, Hatle, L. and Angelsen, B.

35 The pulse repetition frequency f_s can be obtained from

$$f_{S} = \frac{4f_{T}V_{m}}{C} \tag{4}$$

WO 92/03971 1 2 PCT/US91/06206

Thus, for the example given above, $f_s = 160$ kHz.

The corresponding Doppler Shift frequency fp given by equation (2) is 80.0 kHz. This Doppler Shift frequency is obtained, for example, by mixing the backscatter signal with a first local oscillator having a frequency equal to that of the excitation energy. For audible interpretation, The Doppler Shift signal is mixed with a second local oscillator having a frequency of approximately 70 to 75 kHz, resulting in an audible signal within the range of 5 to 10 kHz. If desired, of course, one or more local oscillators may be used to provide either an audible signal, or a detected signal within any desired frequency range.

5

10

15

20

25

30

35

Intravascular Doppler measurements using acoustic fiber (for example, multimode optical fibers) can be made at much higher frequencies compared to the noninvasive case. In the latter, these measurements are made at 2 to 5 MHz because of the attenuation in the body, i.e., ldB/cm/MHz. For a 12 cm round trip, the total attenuation through the body is 60 dB at 5 MHz.

Using acoustic fibers, for a 1 cm round trip in blood, the total attenuation is about 20 dB. Adding the conversion and transmission loss through 1 meter of fiber of approximately 12 dB at 40 MHz yields a path loss of approximately 32 dB in accordance with the teachings of this invention, as compared with a path loss of approximately 60 dB utilizing prior art non-invasive techniques.

Furthermore, in accordance with the teachings of this invention, the coronary arteries are easily reached without any danger of any electrical potentials near the heart wall. The excitation sound is obtained by coupling the input end of optical fiber T (Fig. 4) to an acoustical transducer, such as the circular Interdigital Transducer (IDT) disclosed in the aforementioned copending application of Dias.

Of interest, the use of high frequencies with fibers has the advantageous result that backscattered signals per scatterer is increased and is proportional to f_T^4 , as described by Hatle et al, cited above. Moreover, the receiver bandwidth can be reduced when the pulse length L is made longer and this in turn reduces the receiver noise N.

Hence,

5

s
$$\alpha$$
 $f_T^4 v_{RC}$ (5)

$$N \alpha \frac{1}{L}$$
 (6)

and therefore

$$S/N \alpha = \frac{f_T^4 V_C}{1/L}$$

25 Thus S/N =
$$Kf_T^4 v_{RC} L$$
; where (8)

S = signal from all scatterers;

N = receiver noise;

K = constant of proportionality; and

 v_{pc} = the volume of the range cell.

The S/N at higher frequencies (e.g. 40 MHz)

provides a significant improvement over the S/N

provided by prior art catheter tip PZT transducers

operating at 10 MHz. Furthermore, acoustical

transducer constructed in accordance with the

teachings of this invention are significantly easier

and cheaper to manufacture than prior art PZT

transducers capable of operating at the same, or even

lower, frequencies.

10

15

20

25

30

35

<u>Combined Catheter Tip Blood Velocity Probe and Blood</u> Gas/pH Monitor

Figure 7 depicts one embodiment of a combined catheter tip blood velocity probe and blood gas/pH monitor constructed in accordance with teachings of this invention. Transducer 700 includes a plurality of fibers 725, including for example, acoustical fiber 725-1 and optical fiber 725-2. Transducer 700 also includes guide wire 720 which is useful for guiding the transducer 700 within blood vessel 704. Acoustical fibers 725-1 serve as described above with regard to Figure 4 to measure blood flow velocity within range cell 701. Integrally formed in transducer 700 are optical fibers 725-2 which are used, for example, to measure blood gas concentration in a well-known manner. For example, optical fibers 725-2 are coated on their tips with one or more specific fluorescent dyes. Excitation energy (for example from a laser) is then applied to the proximal ends of fibers 725-2, which is transmitted to the tips in order to excite the dyes. Fluorescent energy is coupled from the dyes to receiving instrumentation at the proximal ends of optical fibers 725-2. The amount of detected fluorescent energy with respect to the amount of excitation optical energy is indicative of the concentration of the blood gas (or pH) which has a specific affinity for the fluorescent dyes used.

If desired, the plurality of optical fibers 725-2 are used with various fluorescent dyes in order to provide a single transducer which measures a plurality of blood gas concentrations, as well as acoustically measuring blood velocity. Furthermore, if desired a single optical fiber is used to couple accoustical and optical energies from their respective sources to the sample being analyzed. Similarly, coupling the accoustical and optical energies from the sample to detection means can be achieved using the same

WO 92/03971 1 5 PCT/US91/06206

optical fiber which is, if desired, the same optical fiber used to couple energies from the energy sources to the sample.

All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.

5

Although the foregoing invention has been
described in some detail by way of illustration and
example for purposes of clarity of understanding, it
will be readily apparent to those of ordinary skill in
the art in light of the teachings of this invention
that certain changes and modifications may be made
thereto without departing from the spirit or scope of
the appended claims.

10

25

WHAT IS CLAIMED IS:

- 1. A sensor for measuring a physical parameter of a fluid flowing within a vessel comprising:
- a source of excitation acoustical energy located outside of said vessel;

means for coupling said excitation acoustical energy to a selected location within said vessel where said physical parameter is to be measured; and

means for coupling returning acoustical energy from said location within said vessel to a measurement device.

- A sensor as in claim 1 wherein said means
 for coupling are housed within a catheter device for insertion into said vessel.
- A sensor as in claim 1 wherein said means for coupling each comprise one or more acoustical
 fibers.
 - 4. A sensor as in claim 1 wherein said means for coupling returning acoustical energy comprises a plurality of acoustical return paths, and said means for coupling excitation acoustical energy is located centrally to said plurality of acoustical return paths.
- 5. A sensor as in claim 1 wherein said physical parameter is fluid flow rate and said returning acoustical energy is Doppler Shifted in frequency from said excitation acoustical energy.
- 6. A sensor as in claim 1 wherein said excitation acoustical energy comprised ultrasonic sound.

WO 92/03971 1 7 PCT/US91/06206

- 7. A sensor as in claim 1 which further comprises one or more fluorescent sensors.
- 8. A sensor as in claim 7 wherein said one or more fluorescent sensors serve to measure the pressures of one or more gasses within said vessel.
- A sensor as in claim 1 which further comprises a wire guide for guiding said sensor within said vessel.
 - 10. A system as in claim 1 which further comprises:
- a source of excitation optical energy located outside of said vessel;

20

means for coupling said excitation optical energy from said source of excitation optical energy to said selected location; and

means for coupling returning optical energy from said selected location to a measurement device for detecting gas concentration.

- 11. A system as in claim 10 wherein said means for coupling said acoustical energies and said means for coupling said optical energies are housed within a catheter device for insertion into said vessel.
- 12. A system as in claim 11 wherein said means for coupling said acoustical energies comprise one or more acoustical fibers and said optical energies comprise one or more optical fibers.
 - 13. A system for measuring fluid flow within a vessel comprising:
- 35 a source of excitation acoustical energy, located outside of said vessel;

WO 92/03971 PCT/US91/06206

a catheter for insertion into said vessel to a selected location at which fluid flow is to be measured;

means for coupling via said catheter said excitation acoustical energy from said source to said selected location;

means for detecting fluid flow in response to returning energy produced as a function of said excitation energy and said fluid flow; and

means for coupling returning energy from said selected location to said means for detecting fluid flow.

5

- 14. A system as in claim 13 wherein said means for coupling each comprise one or more acoustical fibers.
- 15. A system as in claim 13 wherein said means for coupling returning acoustical energy comprises a plurality of acoustical return paths, and said means for coupling excitation acoustical energy is located centrally to said plurality of acoustical return paths.
- 25 16. A system as in claim 13 wherein said returning acoustical energy is Doppler shifted from said excitation acoustical energy as a function of said fluid flow.
- 30 17. A system as in claim 13 wherein said excitation acoustical energy comprises ultrasonic sound.
- 18. A system as in claim 13 which further
 35 comprises:
 - a source of excitation optical energy located outside of said vessel;

WO 92/03971 1 9 PCT/US91/06206

means for coupling via said catheter said excitation optical energy from said source of excitation optical energy to said selected location;

means for detecting gas concentration in response to returning optical energy produced as a function of said excitation optical energy and said gas concentration; and

means for coupling returning optical energy from said selected location to a measurement device for detecting gas concentration.

10

15

20

- 19. A system as in claim 13 wherein said means for coupling said acoustical energies comprise one or more acoustical fibers and said optical energies comprise one or more optical fibers.
- 20. A system as in claim 18 wherein said means for coupling said excitation accoustical energy and said means for coupling said excitation optical energy comprises the same optical fiber.




FIG. 1 (PRIOR ART)




FIG. 2 (PRIOR ART)





FIG. 3






FIG. 5




FIG. 6

5/5




FIG. 7

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)6					
According to International Patent Classification (IPC) or to both National Classification and IPC					
Int.Cl. 5 A61B8/06; A61B5/00; G10K11/24					
1110.01. 0 110.00, 1.2,					
II. FIELDS SEARCHED					
Minimum Documentation Searched?					
Classification Symbols					
Classification System : Classification System					
Int.Cl. 5 A61B; G10K					
int. Gr. 5					
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸					
(D ING DATES)					
•					
,					
III. DOCUMENTS CONSIDERED TO BE RELEVANT 9	Relevant to Claim No.13				
Category Citation of Document, 11 with indication, where appropriate, of the relevant passages 12	1				
THE NAME OF AND ADDRESS OF THE NAME OF THE STATE OF THE S	1-3,6				
Y WO,A,8 907 419 (INTER-THERAPY, INC.) 24 August					
1989 y see page 6, line 4 - line 11	10-13,17				
1 : 0 12 10 - 5566 [] 11BP 3U: [[UUIE 3	9				
	1 2 6				
Y WO,A,8 701 269 (MEDICAL INNOVATION CO.) 12 March	1-3,6				
l 1987	10-13,17				
y see page 4, line 6 - line 19	4, 14, 18				
IA see page 5. line 10 - page /, line 34	19				
A see claims 1-4,7-11; figures 1,2,4					
P.X EP,A,O 397 960 (HEWLETT-PACKARD CO.) 22 November	1-4,				
P,X EP,A,O 397 960 (HEWLETT-PACKARD 60.7 22 NOTEMBER 1990	10-13				
aited in the application					
see column 11, line 9 - line 35; figures 18-20					
-/					
'					
	esignal filling date				
° Special categories of cited documents: 10 T later document published after the inter or priority date and not in conflict with					
"A" document defining the general state of the art which is not cited to understand the principle or meetly and only and					
considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered to					
filing date cannot be considered novel or cannot be considered no					
which is cited to establish the publication date of another and the considered to involve an inventive step when the					
citation or other special reason (as specified) citation or other special reason (as specified) contaction or other special reason (as specified) contaction or other special reason (as specified) document is combined to involve an inventor of the considered to involve and the co					
other means in the art.					
"P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent for					
IV. CERTIFICATION					
Date of the Actual Completion of the International Search Date of Mailing of this International Search	arch Report				
17, 02, 32					
International Searching Authority Signature of Authority	(<i>Ci-</i>)[]				
EUROPEAN PATENT OFFICE RIEB K.D.	1 XILL				

	International Application No	
III. DOCUME	NTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)	
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
	IEEE TRANSACTIONS	7,8,18
A	vol. BME33, no. 2, February 1986, NEW YORK (US) pages 117 - 132;	7,0,10
	J.L. GEHRICH ET AL.: 'Optical Fluorescence and Its Application to an Intravascular Blood Gas	
	Monitoring System' cited in the application see page 119 - page 122; figures 1-3	
		
	•	
	•	

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. US 9106206 SA 53785

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 17/01/92

Patent document cited in search report	Publication date	Patent family member(s)		Publication date	
WO-A-8907419	24-08-89	US-A- AU-A- AU-A- EP-A- JP-T-	4899757 2938689 6761490 0356473 2503279	13-02-90 06-09-89 14-03-91 07-03-90 11-10-90	
WO-A-8701269	12-03-87	AU-A- EP-A-	6371086 0235216	24-03-87 09-09-87	
EP-A-0397960	22-11-90	None			